Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Radiation Oncology›Clinical Question·Updated Jul 2, 2026·v1

Role of SBRT in Oligometastatic NSCLC [GPT-120B RAW]

Evidence-based overview of Role of stereotactic body radiotherapy (SBRT) in metastatic lung cancer.

Moderate Evidence23 references·698 words·3 min read·v1
Radiation Oncologyrole of stereotactic body radiotherapy (sbrt) in metastatic lung cancer
Oligometastatic non‑small cell lung cancer (NSCLC) is increasingly treated with systemic therapy plus stereotactic body radiotherapy (SBRT). Early trials show modest response gains and acceptable toxicity, but survival benefit remains unproven. Guidelines now endorse SBRT for selected patients, emphasizing careful selection and geriatric assessment.

Deep Dive — Evidence Details

References

  1. [1]

    Francolini G, Di Cataldo V, Caini S et al.. “SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial.” The Lancet. Oncology (2026). PMID: 42372744 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
  2. [2]

    Cho BC, Lim SM, Lee SH et al.. “MORPHEUS-Lung: biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer.” Lung cancer (Amsterdam, Netherlands) (2026). PMID: 42103553 ↗

    L2RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
  3. [3]

    McHugh D, Dallos M, Teo MY et al.. “Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41263694 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
  4. [4]

    Ghiringhelli F, Lawrence YR, Felip E et al.. “Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study.” Journal for immunotherapy of cancer (2025). PMID: 40759444 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
  5. [5]

    Wang X, Zhang P, Cao D et al.. “Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy versus gemcitabine and nab-paclitaxel as first-line treatment for recurrent or metastatic pancreatic ductal adenocarcinoma: a randomized, open-label, multicenter, phase III clinical trial (WGOG-PAN 006/ICSBR-2).” Frontiers in immunology (2026). PMID: 42212134 ↗

    L1TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
  6. [6]

    Ma Z, Zhu K, Shi F et al.. “Sintilimab plus fruquintinib with or without radiotherapy for third-line treatment of colorectal cancer with liver metastases: study protocol for a randomized controlled, multicenter phase II trial.” Frontiers in immunology (2026). PMID: 42206059 ↗

    L5TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
  7. [7]

    Olson R, Liu M, Bergman A et al.. “Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2026). PMID: 42140754 ↗

    L4TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
  8. [8]

    Vaynrub M, Bartelstein MK, Yu VY et al.. “Preoperative Stereotactic Body Radiotherapy for Metastatic Bone Disease With Impending Fracture: A Nonrandomized Clinical Trial.” Journal of the National Comprehensive Cancer Network : JNCCN (2026). PMID: 42119606 ↗

    L4TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
  9. [9]

    Wang Y, Xu J, Liang L et al.. “Fruquintinib Plus TAS-102 With or Without SBRT as Third- Or Later-Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase II Trial.” Cancer medicine (2026). PMID: 42057329 ↗

    L4TRIAL_NONRANDOMCited in: Bottom Line, Current Evidence and Standard
  10. [10]

    Helou J, Glicksman R, Bezjak A et al.. “Health-Related Quality of Life After SBRT for Oligoprogressive Disease: Results From a Phase II Prospective Trial.” International journal of radiation oncology, biology, physics (2026). PMID: 41547376 ↗

    L4TRIAL_NONRANDOMCited in: Bottom Line, Current Evidence and Standard
  11. [11]

    So J, Droznin AD, Tiwari P et al.. “Stereotactic Body Radiation Therapy With Pembrolizumab in Programmed Cell Death Protein 1 Inhibitor-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial.” International journal of radiation oncology, biology, physics (2026). PMID: 41520892 ↗

    L4TRIAL_NONRANDOMCited in: Current Evidence and Standard
  12. [12]

    Donovan EK, Schnarr KL, Greenspoon JN et al.. “Stereotactic Body Radiation Therapy Boost Following Urgent 3D Conformal Radiation Therapy for Metastatic Epidural Spinal Cord Compression: A Phase 1 Feasibility Study.” International journal of radiation oncology, biology, physics (2025). PMID: 41448499 ↗

    L4TRIAL_NONRANDOMCited in: Current Evidence and Standard, On the Horizon
  13. [13]

    Winter IW, Smile TD, Videtic GMM. “Approach to Oligometastatic Cancer in the Elderly Patient.” Current oncology reports (2021). PMID: 34448967 ↗

    L5CASE_REPORTCited in: Applicability and Caveats
  14. [14]

    Paioli A, Setola E, Palmerini E et al.. “Experience with eribulin in pretreated patients with advanced liposarcoma: a case series.” Future oncology (London, England) (2019). PMID: 31858818 ↗

    L4CASE_REPORTCited in: Applicability and Caveats
  15. [15]

    Swain M, Ghosh-Laskar S. “Stereotactic body radiotherapy (SBRT) for primary non-metastatic head and neck cancer: When less is enough.” Oral oncology (2021). PMID: 33770592 ↗

    L5REVIEW_NARRATIVECited in: Applicability and Caveats
  16. [16]

    Menoux I, Antoni D, Truntzer P et al.. “Stereotactic body radiation therapy for stage I non-small cell lung carcinomas: Moderate hypofractionation optimizes outcome.” Lung cancer (Amsterdam, Netherlands) (2018). PMID: 30527188 ↗

    L4OTHERCited in: Applicability and Caveats
  17. [17]

    Gogineni E, Rana Z, Wotman M et al.. “Impact of stereotactic body radiation therapy on geriatric assessment and management for older patients with head and neck cancer using G8.” Journal of geriatric oncology (2020). PMID: 32593669 ↗

    L2OTHERCited in: Applicability and Caveats
  18. [18]

    Ost P, Siva S, Brabrand S et al.. “Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial.” The Lancet. Oncology (2025). PMID: 40339593 ↗

    L1RCTCited in: On the Horizon
  19. [19]

    Glicksman RM, Winter J, McPartlin A et al.. “Stereotactic Body Radiation Therapy for Renal Tumors: A Prospective Phase 2 Clinical Trial.” International journal of radiation oncology, biology, physics (2025). PMID: 41290048 ↗

    L4TRIAL_NONRANDOMCited in: On the Horizon
  20. [20]

    Zhang R, Chen M, Yin N et al.. “Low-dose radiation and stereotactic body radiotherapy with PD-1 inhibitor sintilimab and chemotherapy for first-line treatment of locally advanced or metastatic squamous lung cancer: protocol for a randomised phase II trial (IHC002 study).” BMJ open (2025). PMID: 40887121 ↗

    L5TRIAL_NONRANDOMCited in: On the Horizon
  21. [21]

    Filippi AR, Rulli E, Signorelli D et al.. “Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC Regimen.” Clinical lung cancer (2025). PMID: 40781023 ↗

    L5TRIAL_NONRANDOMCited in: On the Horizon
  22. [22]

    Joly A, Blanc Lapierre A, Rio E et al.. “REPAIR_GETUG P16 relapse in previously irradiated prostate bed: a phase I/II study of stereotactic ablative reirradiation potentiated by a metformine study protocol.” BMJ open (2025). PMID: 40707156 ↗

    L5TRIAL_NONRANDOMCited in: On the Horizon
  23. [23]

    Seligmann J, Koessler T, Mauer M et al.. “Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer: results of the EORTC-1560-GITCG multicentre, single-arm phase II study (ILOC).” ESMO open (2025). PMID: 40706222 ↗

    L4TRIAL_NONRANDOMCited in: On the Horizon

Revision History

All updates applied to this page

Loading revisions…